VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster,...
Read More
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019 Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the study License...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced its plans for a Phase 2 clinical study evaluating VBI-1501, the company’s...
Read More
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501 Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PT...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of...
Read More
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest dose Safe and well-tolerated at all doses with no safety signals observed Conference call...
Read More
Presentation to feature overview of positive interim Phase 1 CMV vaccine data and preclinical Zika vaccine data demonstrating neutralizing antibody response VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today...
Read More
Well tolerated at all doses with no safety signals 100% seroconversion at highest dose after two of the three planned vaccinations Dose-dependent antibody responses against CMV gB antigen Full data...
Read More
Cytomegalovirus (“CMV”), a common virus that infects over half of adults by age 40, may cause changes in normal-weight women that could increase the risk of metabolic syndrome says new research...
Read More